ClinicalTrials.gg
TerminatedNCT05559125Updated May 22, 2024

A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects

A Phase 1 interventional study of STSA-1002 Injection and STSA-1005 Injection in Healthy Subject, sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Terminated at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 1, Interventional, and Treatment

Why this study was terminated
Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

An open-label, single-ascending dose phase I study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of STSA-1002 combined with STSA-1005 in healthy subjects.

02

Conditions studied

  • Healthy Subject
03

In context

Lead sponsor

Staidson (Beijing) Biopharmaceuticals Co., Ltd is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects, aged ≥ 18 but ≤ 45, male and female;
  • Weight: Male≥50.0kg, Female ≥ 45kg; : 19.0-26.0 kg/m2, inclusive;
  • Subjects (including their partners) must take effective measures and have no birth plan or sperm or egg donation plan during the trial period and within 6 months after the end of the last administration;
  • The subjects were aware of the risks of the trial, voluntarily participated in the study and signed the form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Have a history of serious disease (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric or cardiovascular diseases) or have undergone any major surgery within 2 months prior to screening;
  • The investigators determined that abnormalities in pre-enrollment physical examinations, laboratory tests, and trial-related tests were ;
  • A definite history of food or drug allergies;
  • Positive screening test results for (HIV) antibodies, syphilis-specific antibody, surface antigen (HBsAg) or antibody (HCVAb);
  • History of tuberculosis; or combined with T-SPOT.TB results, low-dose chest CT comprehensive evaluation of tuberculosis infection;
  • was lower than the lower limit of normal value during the screening period;
  • Smoking more than 5 or equivalent cigarettes per day in the 3 months before screening;
  • Regular drinkers in the 6 months prior to screening, i.e. those who have consumed more than 2 units of alcohol per day (1 unit =360ml beer or 45ml spirits with an alcohol concentration of 40% or 150ml wine) in the 6 months prior to screening or have a positive alcohol test result;
  • Subjects with a history of substance abuse within 1 year before screening or have a positive drug test result;
  • Blood loss or blood donation > 400ml three months before screening, or blood transfusion history within 4 weeks before inclusion;
  • Participate in clinical trials of new drugs or vaccines as a subject within 3 months prior to screening;
  • Vaccination was given within 1 month before screening or planned between the study period and 2 months after the end of the study;
  • Use of medications that may affect immune function in the 6 months prior to screening or any monoclonal antibody or biologic treatment in the 3 months prior to screening and use of prescription drugs/over-the-counter drugs or herbal medicines in the 14 days prior to screening;
  • Drink more than 5 cups of coffee, tea or cola (150ml or more per cup) daily within 3 months before screening;
  • Pregnant or lactating women;
  • A history of blood and needle sickness;
  • Other circumstances in which the investigator considers it inappropriate to participate in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    STSA-1002 and STSA-1005 dose level 1

    Drug: STSA-1002 Injection · Drug: STSA-1005 Injection

  • Experimental
    STSA-1002 and STSA-1005 dose level 2

    Drug: STSA-1002 Injection · Drug: STSA-1005 Injection

  • Experimental
    STSA-1002 and STSA-1005 dose level 3

    Drug: STSA-1002 Injection · Drug: STSA-1005 Injection

  • Experimental
    STSA-1002 and STSA-1005 dose level 4

    Drug: STSA-1002 Injection · Drug: STSA-1005 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events, Clinically Significant Laboratory Abnormalities, Clinically Significant Electrocardiogram、Vital Signs And Physical Examination Abnormalities.

    To evaluate the safety and tolerability of single intravenous administration of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: 56 days

Secondary outcomes

  1. Maximum plasma concentration (Cmax).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344hours postdose

  2. Area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  3. Area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  4. Time of maximum concentration (Tmax)

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344hours postdose

  5. Elimination half-life (t1/2).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  6. Elimination rate constant (Kel).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  7. Clearance (CL).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  8. Apparent volume of distribution (Vz).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  9. Mean residence time (MRTlast).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344 hours postdose

  10. Extrapolated area under the curve (AUC_%Extrap).

    To evaluate the single dose pharmacokinetics (PK) characteristics of STSA-1002 combined with STSA-1005 in healthy adult subjects.

    Time frame: Up to 1344hours postdose

  11. Change from baseline in concentration of free C5a and anti-drug antibody.

    To evaluate the pharmacodynamics (PD) characteristics and immunogenicity of STSA-1002 combined with STSA-1005 in healthy subjects.

    Time frame: Up to 1344 hours postdose

  12. Change from baseline in concentration of cytokine (IL-2, IL-6, IL-8, IL-10, TNF-α, IFN-γ, GM-CSF).

    To evaluate the effects of STSA-1002 combined with STSA-1005 on cytokine (IL-2, IL-6, IL-8, IL-10, TNF-α, IFN-γ, GM-CSF).

    Time frame: Up to 1344 hours postdose

07

Study locations

1 site
  • The Second Affiliated Hospital Of Xingtai Medical College
    Xingtai, Hebei 054000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Mar 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2022
First posted
Sep 29, 2022
StartActual
Nov 8, 2022
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05559125
Responsible party
Sponsor
First posted
Sep 29, 2022
Start date
Nov 8, 2022
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Last update
May 22, 2024

Study contacts

Fengxue Guo, Bachelor
principal investigator · The Second Affiliated Hospital of Xingtai Medical College

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Greziprubart

Start the discussion